AbbVie's Outlook Highly Dependent on Well-Positioned Humira
December 14, 2012 at 07:00 AM EST
A weak pipeline and heavy reliance on one drug support a narrow moat, in contrast to the wide moats of most Big Pharma firms.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.